Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study

Area of Science:

• Uropathology
• Oncology
• Cell Biology

Background:

• Neuroendocrine differentiation in prostatic neoplasms was historically considered rare.
• Previous reports described varied neuroendocrine patterns, often mixed with adenocarcinoma.

Purpose of the Study:

• To investigate the prevalence and characteristics of neuroendocrine differentiation in prostate cancer.
• To highlight the importance of identifying neuroendocrine components for clinical management.

Main Methods:

• Retrospective autopsy review of 2648 cases, identifying 69 prostate carcinomas.
• Histopathological analysis of eight cases with neuroendocrine differentiation.
• Immunohistochemical staining for neuron-specific enolase, prostate-specific antigen (PSA), chromogranin A, synaptophysin, and calcitonin.
• Ultrastructural examination of three cases.

Main Results:

• Eight of 69 prostate carcinomas (11.6%) exhibited neuroendocrine differentiation.
• Five cases were mixed adenocarcinoma-small cell carcinoma, two were pure small cell, and one was carcinoid-like.
• Neuroendocrine areas were positive for neuron-specific enolase (7/8) and chromogranin A (7/8), but negative for PSA (0/8).
• Mean survival after diagnosis was 19 months for patients with neuroendocrine prostate cancer.

Conclusions:

• Neuroendocrine differentiation in prostate cancer appears more frequent than previously recognized.
• Misidentification of neuroendocrine areas as poorly differentiated adenocarcinoma is possible.
• Recognition of neuroendocrine prostate cancer is vital for prognostic assessment and therapeutic decisions.